Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJB001 Combination Therapy in Patients With Advanced Solid Tumors
NCT06953323Phase 2Recruiting
- Sponsor
- Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WJB001 in solid tumor, ovarian cancer, fallopian tube cancer (PFTC) and 2 more (7 arms), sponsored by Wigen Biomedicine Technology (Shanghai) Co., Ltd. Primary endpoints: Dose limited toxicity at 21 days, Adverse event at 3 years and 4 more. Started Jul 2025; status: recruiting.
02
Drugs
WJB001
03
Conditions
solid tumorovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT06953323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953323.